{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:04:08Z","timestamp":1792843448594,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Center for Disease Control via Philadelphia Department of Public Health","award":["No. 1 NH28CE003536-01-00"],"award-info":[{"award-number":["No. 1 NH28CE003536-01-00"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite the emergence of medetomidine as the dominant adulterant in Philadelphia\u2019s illicit opioid supply, coordinated public health responses are limited or non-existent in the literature. Thus, we summarize a recent Summit in Philadelphia of outpatient and inpatient service providers who specialize in the care of persons who use drugs to discuss medetomidine response readiness and building ongoing community readiness for potential destabilizing drug supply changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Describe a public health intervention that distributed information about practices across health care settings and mobilized key informants to identify and address barriers to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Descriptive summary of the in-person Summit organized by the Division of Substance Use Prevention and Harm Reduction at the Philadelphia Department of Public Health and the Health Federation of Philadelphia\u2019s Substance Use Response, Guidance, and Education program to review cases of medetomidine-associated withdrawal across outpatient, emergency department, hospital, and substance use treatment settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The authors reviewed the insights from attendees and grouped them into nine themes: overdose response, clinical recognition of withdrawal, monitoring withdrawal, treatment approach, patient care navigation, workforce development, testing and surveillance, mobile outreach, and reimbursement. The authors subsequently developed twelve summative recommendations to guide further public health interventions in Philadelphia and other communities where medetomidine may become a common adulterant in the drug supply.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The insights gained regarding medetomidine withdrawal management will be shared with community organizations providing services to people who use drugs in Philadelphia and clarify specific barriers and areas for ongoing support. Other communities experiencing shifts in drug supply may benefit from this knowledge and similar information sharing colloquiums.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00713-y","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:07:53Z","timestamp":1788149273000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Responding to medetomidine in Philadelphia: narrative summary of the public health response to a new psychoactive substance"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7650-360X","authenticated-orcid":false,"given":"TaReva","family":"Warrick-Stone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge-Emile","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Durney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Goodstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Bobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kory","family":"London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teixeira da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"713_CR1","unstructured":"Krotulski AJ, Shinefeld J, Moraff C, Wood T, Walton SE, DeBord JS, et al. Medetomidine Rapidly Proliferating Across USA \u2014 Implicated In Recreational Opioid Drug Supply & Causing Overdose Outbreaks [Internet]. Center for Forensic Science Research and Education. 2024 [cited 2026 Feb 2]. Available from: https:\/\/www.cfsre.org\/nps-discovery\/public-alerts\/medetomidine-rapidly-proliferating-across-usa-implicated-in-recreational-opioid-drug-supply-causing-overdose-outbreaks"},{"issue":"5","key":"713_CR2","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1111\/1556-4029.15242","volume":"68","author":"E Sisco","year":"2023","unstructured":"Sisco E, Appley M. Identification of the veterinary sedative medetomidine in combination with opioids and xylazine in Maryland. J Forensic Sci. 2023;68(5):1708\u201312.","journal-title":"J Forensic Sci"},{"issue":"4","key":"713_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/ADM.0000000000001500","volume":"19","author":"Z Nayani","year":"2025","unstructured":"Nayani Z, Reese T, Armstrong A, Walker A, Tani F, Fitzgerald R. Medetomidine-Associated Opioid Overdoses in Chicago, Illinois: A Report of 3 Cases. J Addict Med. 2025;19(4):497\u2013500.","journal-title":"J Addict Med"},{"issue":"30","key":"713_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.15585\/mmwr.mm7330a3","volume":"73","author":"ES Schwarz","year":"2024","unstructured":"Schwarz ES, Buchanan J, Aldy K, Shulman J, Krotulski A, Walton S, et al. Notes from the Field: Detection of Medetomidine Among Patients Evaluated in Emergency Departments for Suspected Opioid Overdoses - Missouri, Colorado, and Pennsylvania, September 2020-December 2023. MMWR Morb Mortal Wkly Rep. 2024;73(30):672\u20134.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"713_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.15585\/mmwr.mm7415a1","volume":"74","author":"A Nham","year":"2025","unstructured":"Nham A, Le JN, Thomas SA, Gressick K, Ussery EN, Ko JY, et al. Overdoses Involving Medetomidine Mixed with Opioids - Chicago, Illinois, May 2024. MMWR Morb Mortal Wkly Rep. 2025;74(15):258\u201365.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"713_CR6","unstructured":"Franklin F, Best A, Teixeira Da Silva D. Health Alert: In Philadelphia, medetomidine, a potent non-opioid veterinary sedative, has been detected in the illicit drug supply [Internet]. Philadelphia Department of Public Health. 2024 [cited 2026 Jan 26]. Available from: http:\/\/hip.phila.gov\/document\/4421\/PDPH-HAN-0441A-05-13-24.pdf"},{"issue":"21","key":"713_CR7","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1021\/acschemneuro.4c00583","volume":"15","author":"P de Andrade Horn","year":"2024","unstructured":"de Andrade Horn P, Berida TI, Parr LC, Bouchard JL, Jayakodiarachchi N, Schultz DC, et al. Classics in chemical neuroscience: medetomidine. ACS Chem Neurosci. 2024;15(21):3874\u201383.","journal-title":"ACS Chem Neurosci"},{"key":"713_CR8","unstructured":"PA Groundhogs. PAG Releases New Adulterant Report [Internet]. PA Groundhogs. 2025 [cited 2026 Jan 9]. Available from: https:\/\/pagroundhogs.org\/news\/f\/pag-releases-new-adulterant-report"},{"key":"713_CR9","unstructured":"Franklin F, Laboy C, Teixeira Da Silva D. Health Alert: Hospitals and behavioral health providers are reporting severe and worsening presentations of withdrawal among people who use drugs (PWUD) in Philadelphia [Internet]. Philadelphia Department of Public Health. 2024 [cited 2026 Jan 25]. Available from: http:\/\/hip.phila.gov\/document\/4874\/PDPH-HAN-00444A-12-10-2024.pdf\/."},{"key":"713_CR10","unstructured":"Puleo M, Ward N, Higgins D, Teixeira da Silva D. CHART: Changes in Philadelphia\u2019s drug supply andsubstance use-related emergency department visits [Internet]. Philadelphia Department of Public Health. 2025 [cited 2026 Jan 24]. Available from: https:\/\/www.phila.gov\/media\/20250523124235\/CHART-v10-e1.pdf"},{"key":"713_CR11","unstructured":"U.S. Centers for Disease Control and Prevention. Medetomidine in the U.S. Illegal Fentanyl Supply Increasing Risk for Overdose and Severe Withdrawal Syndrome [Internet]. CDC Health Alert Network (HAN). 2026 [cited 2026 Apr 4]. Available from: https:\/\/www.cdc.gov\/han\/php\/notices\/han00527.html"},{"issue":"15","key":"713_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.15585\/mmwr.mm7415a3","volume":"74","author":"SJ Ostrowski","year":"2025","unstructured":"Ostrowski SJ, Tamama K, Trautman WJ, Stratton DL, Lynch MJ. Notes from the Field: Severe Medetomidine Withdrawal Syndrome in Patients Using Illegally Manufactured Opioids - Pittsburgh, Pennsylvania, October 2024-March 2025. MMWR Morb Mortal Wkly Rep. 2025;74(15):269\u201371.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"713_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.15585\/mmwr.mm7415a2","volume":"74","author":"S Huo","year":"2025","unstructured":"Huo S, London K, Murphy L, Casey E, Durney P, Arora M, et al. Notes from the Field: Suspected Medetomidine Withdrawal Syndrome Among Fentanyl-Exposed Patients - Philadelphia, Pennsylvania, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025;74(15):266\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"713_CR14","doi-asserted-by":"crossref","unstructured":"London KS, Huo S, Murphy L, Warrick-Stone T, Goodstein D, Montesi M et al. Severe fentanyl withdrawal associated with medetomidine adulteration: A multicenter study from philadelphia, PA. J Addict Med. 2025.","DOI":"10.1097\/ADM.0000000000001560"},{"issue":"2","key":"713_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/biomed5020013","volume":"5","author":"KS London","year":"2025","unstructured":"London KS, Durney P, Warrick-Stone T, Alexander K, Kahoud JL. Decreased effectiveness of a novel opioid withdrawal protocol following the emergence of medetomidine as a fentanyl adulterant. biomed. 2025;5(2):13.","journal-title":"biomed"},{"issue":"4","key":"713_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/psychoactives4040037","volume":"4","author":"P Durney","year":"2025","unstructured":"Durney P, Paquin E, Fitzpatrick G, Lockstein D, Warrick-Stone T, Montesi M, et al. Profound opioid and medetomidine withdrawal: A case series and narrative review of available literature. Psychoactives. 2025;4(4):37.","journal-title":"Psychoactives"},{"key":"713_CR17","doi-asserted-by":"crossref","unstructured":"Lynch MJ, Pizon AF, Yealy DM. Emergence of medetomidine in the illicit drug supply: implications for emergency care and withdrawal management. Ann Emerg Med. 2026.","DOI":"10.1016\/j.annemergmed.2025.12.004"},{"key":"713_CR18","doi-asserted-by":"crossref","unstructured":"Huo S, Perrone J. The shifting landscape of a fentanyl adulterant: moving from xylazine to medetomidine. J Addict Med. 2025.","DOI":"10.1097\/ADM.0000000000001592"},{"key":"713_CR19","unstructured":"Raval-Nelson P, Franklin F, Teixeira Da Silva D. Health Update: Responding to overdose and withdrawal involving medetomidine [Internet]. Philadelphia Department of Public Health. 2025 [cited 2026 Jan 22]. Available from: https:\/\/hip.phila.gov\/document\/5444\/PDPH-HAN-SUPHR-Medetomidine-06.10.2025_1Zu1OZ4.pdf\/."},{"key":"713_CR20","doi-asserted-by":"crossref","unstructured":"Durney P, Kahoud JL, Warrick-Stone T, Montesi M, Carter M, Butt S et al. Biochemical identification and clinical description of medetomidine exposure in people who use fentanyl in Philadelphia, PA. Int J Mol Sci. 2025;26(14).","DOI":"10.3390\/ijms26146715"},{"issue":"17","key":"713_CR21","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/jama.2024.15992","volume":"332","author":"JJ Palamar","year":"2024","unstructured":"Palamar JJ, Krotulski AJ. Medetomidine infiltrates the US illicit opioid market. JAMA. 2024;332(17):1425\u20136.","journal-title":"JAMA"},{"key":"713_CR22","first-page":"101053","volume":"44","author":"DT Zhu","year":"2025","unstructured":"Zhu DT, Palamar JJ. Responding to medetomidine: clinical and public health needs. Lancet Reg Health Am. 2025;44:101053.","journal-title":"Lancet Reg Health Am"},{"issue":"5","key":"713_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1111\/ajad.70030","volume":"34","author":"N Sood","year":"2025","unstructured":"Sood N. Rise of illicit medetomidine use: A worrisome trend. Am J Addict. 2025;34(5):558\u201361.","journal-title":"Am J Addict"},{"key":"713_CR24","unstructured":"Philadelphia Department of Public Health, Division of Substance Use Prevention and Harm Reduction. Medetomidine: What you need to know about the new street drug taking over Philly [Internet]. Substance Use Philly. 2025 [cited 2026 Jan 23]. Available from: https:\/\/www.substanceusephilly.com\/medetomidine"},{"key":"713_CR25","unstructured":"Philadelphia Department of Public Health. Division of Substance Use Prevention and Harm Reduction. Recommendations for caring for individuals with xylazine-associated wounds. 2024."},{"issue":"5","key":"713_CR26","doi-asserted-by":"publisher","first-page":"102248","DOI":"10.1016\/j.outlook.2024.102248","volume":"72","author":"C Tomson","year":"2024","unstructured":"Tomson C, Neuschatz R, Teixeira da Silva D. Harm reduction nursing and the path toward developing best practice: Lessons from caring for people with xylazine-associated wounds in Philadelphia, PA. Nurs Outlook. 2024;72(5):102248.","journal-title":"Nurs Outlook"},{"key":"713_CR27","unstructured":"National Fetal and Infant Mortality Review Program. Fetal and Infant Mortality Review Manual: A Guide for Communities. 2nd Edition. 2008."},{"key":"713_CR28","unstructured":"American Society of Addiction Medicine. About the ASAM Criteria [Internet]. American Society of Addiction Medicine. 2026 [cited 2026 Jan 30]. Available from: https:\/\/www.asam.org\/asam-criteria\/about-the-asam-criteria"},{"key":"713_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1192\/bjp.149.2.235","volume":"149","author":"GT Phillips","year":"1986","unstructured":"Phillips GT, Gossop M, Bradley B. The influence of psychological factors on the opiate withdrawal syndrome. Br J Psychiatry. 1986;149:235\u20138.","journal-title":"Br J Psychiatry"},{"issue":"2","key":"713_CR30","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","volume":"35","author":"DR Wesson","year":"2003","unstructured":"Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoact Drugs. 2003;35(2):253\u20139.","journal-title":"J Psychoact Drugs"},{"key":"713_CR31","unstructured":"Pennsylvania Department of Human Services Statewide Preferred Drug List [Internet]. Commonwealth of Pennsylvania. 2026 [cited 2026 Mar 30]. Available from: https:\/\/www.papdl.com\/"},{"issue":"3","key":"713_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/clpt.1985.171","volume":"38","author":"TR MacGregor","year":"1985","unstructured":"MacGregor TR, Matzek KM, Keirns JJ, van Wayjen RG, van den Ende A, van Tol RG. Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther. 1985;38(3):278\u201384.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"713_CR33","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/S0952-8180(05)80018-2","volume":"6","author":"FE Cunningham","year":"1994","unstructured":"Cunningham FE, Baughman VL, Peters J, Laurito CE. Comparative pharmacokinetics of oral versus sublingual clonidine. J Clin Anesth. 1994;6(5):430\u20133.","journal-title":"J Clin Anesth"},{"issue":"1","key":"713_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/AOG.0000000000006110","volume":"147","author":"CW Jones","year":"2026","unstructured":"Jones CW, Manriquez M, Chavan NR. Emerging substances and perinatal health: A narrative review. Obstet Gynecol. 2026;147(1):64\u201372.","journal-title":"Obstet Gynecol"},{"key":"713_CR35","unstructured":"Briggs GG, Towers CV, Forinash AB. Briggs Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 12th ed. Wolters Kluwer; 2022."},{"issue":"7","key":"713_CR36","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1176\/ps.2006.57.7.992","volume":"57","author":"TE Martinez","year":"2006","unstructured":"Martinez TE, Burt MR. Impact of permanent supportive housing on the use of acute care health services by homeless adults. Psychiatr Serv. 2006;57(7):992\u20139.","journal-title":"Psychiatr Serv"},{"issue":"12","key":"713_CR37","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/dta.3947","volume":"17","author":"E Sisco","year":"2025","unstructured":"Sisco E, Ventura M, Shuda SA. Enantiomeric Determination of Medetomidine in Street Drug Samples (August 2024-February 2025) and Implications for Immunoassay Test Strip Analysis. Drug Test Anal. 2025;17(12):2347\u201353.","journal-title":"Drug Test Anal"},{"issue":"1","key":"713_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12954-024-01052-4","volume":"21","author":"K Hill","year":"2024","unstructured":"Hill K, Minahan-Rowley R, Biegacki ET, Heimer R, Sue KL. Providers\u2019 knowledge and perception of xylazine in the unregulated drug supply: a sequential explanatory mixed-methods study. Harm Reduct J. 2024;21(1):148.","journal-title":"Harm Reduct J"},{"issue":"6","key":"713_CR39","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/15563650.2025.2500601","volume":"63","author":"L Murphy","year":"2025","unstructured":"Murphy L, Krotulski A, Hart B, Wong M, Overton R, McKeever R. Clinical characteristics of patients exposed to medetomidine in the illicit opioid drug supply in Philadelphia - a case series. Clin Toxicol (Phila). 2025;63(6):438\u201341.","journal-title":"Clin Toxicol (Phila)"},{"issue":"10209","key":"713_CR40","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S0140-6736(19)32231-7","volume":"394","author":"A Peacock","year":"2019","unstructured":"Peacock A, Bruno R, Gisev N, Degenhardt L, Hall W, Sedefov R, et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses. Lancet. 2019;394(10209):1668\u201384.","journal-title":"Lancet"},{"issue":"8","key":"713_CR41","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/jat\/bkaf040","volume":"49","author":"SE Walton","year":"2025","unstructured":"Walton SE, Stang BN, Kacinko S, Papsun DM, Logan BK, Krotulski AJ. Medetomidine quantitation and enantiomer differentiation in biological specimens collected after fatal and non-fatal opioid overdoses. J Anal Toxicol. 2025;49(8):551\u20138.","journal-title":"J Anal Toxicol"},{"issue":"4","key":"713_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/YCO.0000000000000938","volume":"37","author":"ND Fitzgerald","year":"2024","unstructured":"Fitzgerald ND, Cottler LB, Palamar JJ. Public health surveillance of new psychoactive substances: recent developments. Curr Opin Psychiatry. 2024;37(4):270\u20136.","journal-title":"Curr Opin Psychiatry"},{"issue":"1","key":"713_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12954-023-00879-7","volume":"20","author":"CM Zagorski","year":"2023","unstructured":"Zagorski CM, Hosey RA, Moraff C, Ferguson A, Figgatt M, Aronowitz S, et al. Reducing the harms of xylazine: clinical approaches, research deficits, and public health context. Harm Reduct J. 2023;20(1):141.","journal-title":"Harm Reduct J"},{"issue":"1","key":"713_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12954-025-01387-6","volume":"23","author":"A Amate","year":"2026","unstructured":"Amate A, Lieberman M. Chiral sensitivity of medetomidine lateral flow immunoassay test strips. Harm Reduct J. 2026;23(1):19.","journal-title":"Harm Reduct J"},{"issue":"1","key":"713_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12954-022-00716-3","volume":"20","author":"I Volpe","year":"2023","unstructured":"Volpe I, Brien R, Grigg J, Tzanetis S, Crawford S, Lyons T, et al. We don\u2019t live in a harm reduction world, we live in a prohibition world: tensions arising in the design of drug alerts. Harm Reduct J. 2023;20(1):3.","journal-title":"Harm Reduct J"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00713-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00713-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:07:55Z","timestamp":1788149275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00713-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["713"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00713-y","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TWS discloses that she receives salary support though Gilead FOCUS for infectious disease screening work; DTdS discloses he is a shareholder of Atai life sciences, Cybin Inc, Compass pathways.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"64"}}